GRCE (Grace Therapeutics) Current Accrued Expense: $0.73 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GRCE Grace Therapeutics Inc GRCE
31 GF Score
Price $2.07
! 2 Warning Signs
View Full Analysis

What is Grace Therapeutics Current Accrued Expense?

Grace Therapeutics GRCE -1.90% 31 Current Accrued Expense is $0.73 Mil as of Mar. 2026. GuruFocus rates GRCE with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

Grace Therapeutics's Current Accrued Expense for the quarter that ended in Mar. 2026 was $0.73 Mil.

Grace Therapeutics's quarterly Current Accrued Expense increased from Sep. 2025 ($0.37 Mil) to Dec. 2025 ($0.62 Mil) and increased from Dec. 2025 ($0.62 Mil) to Mar. 2026 ($0.73 Mil).

Grace Therapeutics's annual Current Accrued Expense increased from Mar. 2024 ($0.18 Mil) to Mar. 2025 ($0.67 Mil) and increased from Mar. 2025 ($0.67 Mil) to Mar. 2026 ($0.73 Mil).

Grace Therapeutics Current Accrued Expense Related Terms

Grace Therapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Grace Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grace Therapeutics Current Accrued Expense Chart

Grace Therapeutics Annual Data
Trend Feb16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.30 0.95 0.18 0.67 0.73

Grace Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.67 0.67 0.37 0.62 0.73
GRCE
31GF Score
Grace Therapeutics Inc GRCE
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grace Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.73 Mil mean?
Grace Therapeutics (GRCE) has a Current Accrued Expense of $0.73 Mil as of Mar. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Grace Therapeutics and its competitors.
Is Grace Therapeutics' Current Accrued Expense too high?
Grace Therapeutics' current Current Accrued Expense is $0.73 Mil. Overall, Grace Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Grace Therapeutics' Current Accrued Expense compare to PDSB and HYPD?
Grace Therapeutics' Current Accrued Expense of $0.73 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Grace Therapeutics and its competitors. Grace Therapeutics's current Current Accrued Expense is $0.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grace Therapeutics stock overvalued right now?
Grace Therapeutics (GRCE) has a current Current Accrued Expense of $0.73 Mil. The current Current Accrued Expense is $0.73 Mil. Grace Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Grace Therapeutics (GRCE), the current Current Accrued Expense is $0.73 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Grace Therapeutics Business Description

Address 103 Carnegie Center, Suite 300, Princeton, NJ, USA, 08540
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
31GF Score

Get the complete analysis for GRCE

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.07
Price